Skip to main content

Table 3 Comparison of clinical characteristics in survival and non-survival groups in 52 children with P. aeruginosa bacteremia

From: Prognostic role of time to positivity of blood culture in children with Pseudomonas aeruginosa bacteremia

Characteristics Non-survival
(n = 12)
Survival
(n = 40)
P values
Basic information
 Age(years) (median, IQR) 1.55(0.21–9.80) 1.79(0.44–9.01) 0.373
 Male (n, %) 8(66.7%) 24(60.0%) 0.938
 Weight (kilogram) (median, IQR) 10.00(4.85–29.88) 11.25(7.00–27.00) 0.521
Underlying diseases
 Hematologic malignancies (n, %) 2(16.7%) 14(35.0%) 0.395
 Congenital heart disease (n, %) 1(8.3%) 6(12.5%) 1.000
Underlying conditions
 Immunosuppression (n, %) 5(41.7%) 21(52.5%) 0.743
 Neutropenia (n, %) 8(66.7%) 16(40.0%) 0.195
 Hypoalbuminemia (n, %) 9(75.0%) 13(32.5%) 0.023*
Complications
 Pneumonia (n, %) 3(25.0%) 6(15.0%) 0.129
 Meningitis (n, %) 2(16.7%) 3(7.5%) 0.699
 Peritonitis (n, %) 0(0.0%) 3(7.5%) 0.333
Origins of infection
 Respiratory tract (n, %) 6(50.0%) 16(40.0%) 0.740
 Primary bacteremia (n, %) 1(8.3%) 6(15.0%) 0.911
 Vascular-catheter related infection (n, %) 1(8.3%) 7(17.5%) 0.752
 Soft tissue infection (n, %) 3(25.3%) 5(12.5%) 0.551
 Gastrointestinal infection (n, %) 1(8.3%) 4(10.0%) 1.000
 Post-surgery or-procedure bacteremia (n, %) 0(0.0%) 2(5.0%) 0.434
Intensive unit care (n, %) 6(50.0%) 14(35.0%) 0.500
Nosocomial infection (n, %) 4(33.3%) 18(45.0%) 0.701
Pittsburgh bacteremia scores (median, IQR) 4.50(1.25–7.25) 1.00(1.00–3.75) 0.043*
Antibiotics administration before blood culture (n, %) 7(58.3%) 24(60.0%) 1.000
Inappropriate empirical antimicrobial therapy (n, %) 5(41.7%) 9(22.5%) 0.267
TTP (median, IQR) 15.19(11.21–18.24) 19.42(16.92–20.97) 0.005*
Length of hospitalization days (median, IQR) 2.86(2.07–28.08) 26.44(19.80–44.63) 0.002*
Multi-drug resistance bacteria (n, %) 0(0.0%) 4(10.0%) 0.259
Septic shock (n, %) 7(58.3%) 8(20.0%) 0.025*
  1. * Indicates statistical significant results, P<0.05